The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps

Rhinology
E De SchryverPhilippe Gevaert

Abstract

Periostin is a recently discovered biomarker for eosinophilic inflammation. Chronic rhinosinusitis with nasal polyps is a T-helper 2-skewed chronic inflammatory airway disease. Medical treatments aim to relieve symptoms and maintain clinical control by interfering with the inflammatory cascade. The effect on nasal and serum periostin levels is however yet unknown. We aimed to evaluate the effect of omalizumab, mepolizumab, methylprednisolone and doxycycline on nasal and systemic periostin expression. This study is based on 3 previously published trials. Nasal and systemic periostin were assessed in CRSwNP patients, randomly assigned to receive doxycycline (n=14), methylprednisolone (n=14), mepolizumab (n=20) or omalizumab (n=15). There was a control group for each treatment scheme. Doxycycline (200 mg on the first day, followed by 100 mg once daily) and methylprednisolone (32-8 mg once daily) were administered during 20 days; mepolizumab was injected at baseline and at 4 weeks. Omalizumab was injected every 2 or 4 weeks, following the official drug leaflet. Methylprednisolone and omalizumab significantly reduced serum periostin levels at 4 and 8 weeks, respectively, after the start of the treatment. The effect of methylpredniso...Continue Reading

Citations

Jun 15, 2018·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P CampoC Rondon
Oct 26, 2018·American Journal of Rhinology & Allergy·Nuray Bayar MulukGuy Scadding
Apr 3, 2019·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Ashton E LehmannRalph Metson
May 15, 2019·Current Opinion in Allergy and Clinical Immunology·Chengshuo Wang, Luo Zhang
Oct 11, 2019·Expert Review of Clinical Immunology·Hongfei LouLuo Zhang
Jan 29, 2020·Expert Review of Clinical Immunology·Chengshuo WangLuo Zhang
Sep 22, 2020·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Lei YuKai Liu
Apr 10, 2019·Allergy·Kenji IzuharaAtsushi Kawaguchi
Dec 17, 2020·International Journal of Molecular Sciences·Annina LylySanna Toppila-Salmi
Mar 7, 2021·The Journal of Allergy and Clinical Immunology·Di WuLuo Zhang
Sep 19, 2021·Clinical Reviews in Allergy & Immunology·Philippe GevaertTara F Carr
Nov 19, 2021·Current Opinion in Allergy and Clinical Immunology·Cui-Lian GuoZheng Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
W-L LiuH-B Li
Polskie Archiwum Medycyny Wewnętrznej
Charles McSharry, Steven Johnstone
The Journal of Allergy and Clinical Immunology
Philippe GevaertClaus Bachert
© 2022 Meta ULC. All rights reserved